Dimensional Fund Advisors
DNLI icon

Dimensional Fund Advisors’s Denali Therapeutics DNLI Stock Holding History

Dimensional Fund Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.6M Buy
2,860,604
+168,429
+6% +$3.46M 0.01% 1384
2026
Q1 		$51.7M Buy
2,692,175
+317,872
+13% +$6.32M 0.01% 1482
2025
Q4 		$39.2M Buy
2,374,303
+17,089
+0.7% +$288K 0.01% 1633
2025
Q3 		$34.2M Sell
2,357,214
-55,714
-2% -$801K 0.01% 1726
2025
Q2 		$33.8M Buy
2,412,928
+312,072
+15% +$4.39M 0.01% 1714
2025
Q1 		$28.6M Buy
2,100,856
+245,820
+13% +$4.71M 0.01% 1774
2024
Q4 		$37.8M Buy
1,855,036
+295,594
+19% +$7.57M 0.01% 1684
2024
Q3 		$45.4M Buy
1,559,442
+141,970
+10% +$3.52M 0.01% 1562
2024
Q2 		$32.9M Buy
1,417,472
+84,522
+6% +$1.62M 0.01% 1702
2024
Q1 		$27.4M Buy
1,332,950
+213,322
+19% +$4.01M 0.01% 1828
2023
Q4 		$24M Buy
1,119,628
+146,394
+15% +$2.9M 0.01% 1894
2023
Q3 		$20.1M Buy
973,234
+218,433
+29% +$5.54M 0.01% 1916
2023
Q2 		$22.3M Buy
754,801
+127,476
+20% +$3.58M 0.01% 1881
2023
Q1 		$14.4M Buy
+627,325
New +$17.3M ﹤0.01% 2063
2022
Q3 		$18.7M Sell
609,839
-281,839
-32% -$9.16M 0.01% 1873
2022
Q2 		$26.2M Buy
891,678
+13,454
+2% +$352K 0.01% 1708
2022
Q1 		$28.3M Buy
878,224
+106,027
+14% +$3.65M 0.01% 1788
2021
Q4 		$34.4M Buy
772,197
+137,462
+22% +$6.51M 0.01% 1670
2021
Q3 		$32M Buy
634,735
+309,387
+95% +$17.4M 0.01% 1743
2021
Q2 		$25.5M Sell
325,348
-95,854
-23% -$5.93M 0.01% 1934
2021
Q1 		$24M Sell
421,202
-31,578
-7% -$2.11M 0.01% 1946
2020
Q4 		$37.9M Sell
452,780
-82,339
-15% -$4.98M 0.01% 1587
2020
Q3 		$19.2M Sell
535,119
-15,578
-3% -$469K 0.01% 1876
2020
Q2 		$13.3M Sell
550,697
-13,162
-2% -$309K 0.01% 2081
2020
Q1 		$9.88M Buy
563,859
+42,193
+8% +$880K 0.01% 2126
2019
Q4 		$9.09M Buy
521,666
+123,343
+31% +$2.05M ﹤0.01% 2388
2019
Q3 		$6.1M Buy
398,323
+193,781
+95% +$3.7M ﹤0.01% 2536
2019
Q2 		$4.25M Buy
+204,542
New +$4.58M ﹤0.01% 2690

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors's DNLI Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Denali Therapeutics (DNLI) stake by 6.3% in Q2 2026, buying an estimated $3.46M and bringing the position to 2,860,604 shares worth $73.6M. The position accounts for 0.01% of the portfolio, ranked #1384.

Dimensional Fund Advisors first reported a position in DNLI in Q2 2019 and has held it in 28 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Dimensional Fund Advisors held 2,860,604 shares of Denali Therapeutics worth $73.6M as of Q2 2026.
  • Dimensional Fund Advisors bought 168,429 Denali Therapeutics shares in Q2 2026, an estimated $3.46M.
  • Denali Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1384 holding.
  • Dimensional Fund Advisors first reported a position in Denali Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.